A latest FCF Life Sciences evaluation confirmed a major decline in funding volumes for European life sciences markets within the first half of 2022 in comparison with 2021. This pattern is now confirmed for the US life sciences markets as properly. It impacts all related subsectors, specifically Biotech and HealthTech.
The full financing volumes declined by nearly 1 / 4 from USD 45.1bn to USD 34.9bn. The HealthTech subsector has been particularly affected with a discount in funding by greater than -35 %.
Curiously, solely Sequence B corporations have been capable of entice extra funding. The excess is partly attributable to 2 offers within the MedTech sector: Noah Medical (USD 150m) and Biolinq (USD 116m). If excluded, the funding scenario for Sequence B corporations would additionally flip detrimental in H1/2022, leading to a decline in funding for corporations throughout all levels.